A subcutaneous answer to PD-1’s patent problem
PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.
World Lung 2023 preview – Astra’s Tagrisso showdown
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.
Astra goes pivotal with CTLA-4
Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently.
Immatics builds on its PRAME success
PRAME has become a hot target for Immatics, which is now clinically progressing two different modalities against this antigen.
Lilly calls time on IDH1/2 inhibition
Servier's vorasidenib had shown promise at ASCO, but Lilly's dual IDH project LY3410738 leaves the pipeline.
